Speak directly to the analyst to clarify any post sales queries you may have.
Geographic Atrophy Pipeline Review, H2 2018
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Geographic Atrophy Pipeline Review, H2 2018, provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape.
Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract surgery. Treatment includes visual rehabilitation that can help with contrast sensibility and reading ability.
Report Highlights
This latest pipeline guide Geographic Atrophy Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Geographic Atrophy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Geographic Atrophy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Geographic Atrophy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Geographic Atrophy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Geographic Atrophy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Geographic Atrophy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Geographic Atrophy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Geographic Atrophy (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Geographic Atrophy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Geographic Atrophy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Report Coverage
Geographic Atrophy - Overview
Geographic Atrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Geographic Atrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Geographic Atrophy - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc
Acucela Inc
Alkeus Pharmaceuticals Inc
Allergan Plc
Apellis Pharmaceuticals Inc
Cell Cure Neurosciences Ltd
Colby Pharmaceutical Co
F. Hoffmann-La Roche Ltd
Foamix Pharmaceuticals Ltd
Genentech Inc
GenSight Biologics SA
Ionis Pharmaceuticals Inc
Johnson & Johnson
Novartis AG
NovelMed Therapeutics Inc
Ophthotech Corp
Ra Pharmaceuticals Inc
Geographic Atrophy - Drug Profiles
ACH-5548 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACU-6151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLG-561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPC-551 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMR-59 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FB-LRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPE-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-5072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OpRegen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palucorcel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6147 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7171009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Inhibit Complement Factor D for Dry (atrophic) Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit Complement Factor D for Geographic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 3 to Inhibit Complement Factor D for Geographic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Factor D for Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Geographic Atrophy - Dormant Projects
Geographic Atrophy - Discontinued Products
Geographic Atrophy - Product Development Milestones
Featured News & Press Releases
Jul 24, 2018: Apellis Pharmaceuticals APL-2 receives fast track designation from FDA for the treatment of patients with geographic atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Geographic Atrophy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Geographic Atrophy - Pipeline by Achillion Pharmaceuticals Inc, H2 2018
Geographic Atrophy - Pipeline by Acucela Inc, H2 2018
Geographic Atrophy - Pipeline by Alkeus Pharmaceuticals Inc, H2 2018
Geographic Atrophy - Pipeline by Allergan Plc, H2 2018
Geographic Atrophy - Pipeline by Apellis Pharmaceuticals Inc, H2 2018
Geographic Atrophy - Pipeline by Cell Cure Neurosciences Ltd, H2 2018
Geographic Atrophy - Pipeline by Colby Pharmaceutical Co, H2 2018
Geographic Atrophy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Geographic Atrophy - Pipeline by Foamix Pharmaceuticals Ltd, H2 2018
Geographic Atrophy - Pipeline by Genentech Inc, H2 2018
Geographic Atrophy - Pipeline by GenSight Biologics SA, H2 2018
Geographic Atrophy - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Geographic Atrophy - Pipeline by Johnson & Johnson, H2 2018
Geographic Atrophy - Pipeline by Novartis AG, H2 2018
Geographic Atrophy - Pipeline by NovelMed Therapeutics Inc, H2 2018
Geographic Atrophy - Pipeline by Ophthotech Corp, H2 2018
Geographic Atrophy - Pipeline by Ra Pharmaceuticals Inc, H2 2018
Geographic Atrophy - Dormant Projects, H2 2018
Geographic Atrophy - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Geographic Atrophy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achillion Pharmaceuticals Inc
- Acucela Inc
- Alkeus Pharmaceuticals Inc
- Allergan Plc
- Apellis Pharmaceuticals Inc
- Cell Cure Neurosciences Ltd
- Colby Pharmaceutical Co
- F. Hoffmann-La Roche Ltd
- Foamix Pharmaceuticals Ltd
- Genentech Inc
- GenSight Biologics SA
- Ionis Pharmaceuticals Inc
- Johnson & Johnson
- Novartis AG
- NovelMed Therapeutics Inc
- Ophthotech Corp
- Ra Pharmaceuticals Inc
